Cytodigm’s proprietary lipid nanoparticle (LNP) and lipoplex nanoparticle (LPP) platforms advance non-viral delivery by improving extrahepatic targeting, biodistribution, repeat dosing capability, and payload versatility. These technologies support DNA, mRNA, gene editing tools, in vivo CAR constructs, siRNA, and antisense oligonucleotides (ASOs)—enabling novel therapeutic approaches across multiple disease areas.
By advancing delivery science and broadening the reach of genetic medicines, Cytodigm’s platforms provide a strong foundation for developing more precise, effective in vivo cell and gene therapies and accelerating the next generation of treatment innovation.
Cytofinity™ LNPs utilize a PEG-free design, replacing traditional PEG-lipids with sialic acid (SA)-containing gangliosides that eliminate PEG-mediated immunogenicity and enhance tissue targeting.
Pulmofinity™ PEG-free LPPs were developed for exclusive lung tropism via systemic dosing, supporting applications associated with a variety of pulmonary diseases.
Together, these platforms expand the range of tissues, delivery routes, and therapeutic applications that can be targeted in vivo, supporting the development of next-generation genetic medicines.
| TARGET TISSUE | Delivery Platform | Features | Application Areas |
|---|---|---|---|
 LIVER |
|
| |
 LUNG (inhalation) |
|
| |
 LUNG (systemic routes) |
|
| |
 EYE(intravitreal) |
|
| |
 SPLEEN |
|
|
Cytofinity™ is a PEG-free lipid nanoparticle (LNP) system engineered for targeted delivery of nucleic acid therapeutics. By replacing PEG-lipids with sialic acid-containing gangliosides that engage Siglec receptors, Cytofinity improves biodistribution, reduces undesired immunogenicity, supports repeat dosing, and allows for cell targeting without conjugation.
Pulmofinity™ lipoplex nanoparticles (LPPs) enable targeted delivery of nucleic acid payloads to the lung via systemic administration. Leveraging receptor-binding ligands such as polysialic acid (PSA), Pulmofinity supports delivery of mRNA, siRNA, and antisense oligonucleotides (ASOs) with strong pulmonary specificity.
